Evaluation of recurrent parasitemia after artemether-lumefantrine treatment for uncomplicated malaria in children in western Kenya.
From April 2005 to April 2006, a phase 2 malaria vaccine trial in Kenya enrolled 400 children aged 12-47 months. Each received mixed supervised and unsupervised artemether-lumefantrine for uncomplicated malaria, using a standard six-dose regimen, by weight. Children were followed for detection of parasitemia and clinical malaria. A median of two negative malaria blood films occurred during every recurrent parasitemia (RP) episode, suggesting reinfection over late recrudescence. Median time to RP after starting artemether-lumefantrine was 37 days (36-38). Of 2,020 evaluable artemether-lumefantrine treatments, there were no RPs in 99% by day 14, 71% by day 28, and 41% by day 42. By World Health Organization standards, 71% of treatment courses had adequate responses. Although recrudescence in some cannot be ruled out, our cohort had a shorter median time to RP compared with other artemether-lumefantrine treatment studies. This underscores patient counseling on completing all treatment doses for optimal protection from RP.
Woodring
Joseph V
JV
Walter Reed Army Institute of Research, Silver Spring, Maryland, USA. joseph.woodring@us.army.mil
Ogutu
Bernhards
B
Schnabel
David
D
Waitumbi
John N
JN
Olsen
Cara H
CH
Walsh
Douglas S
DS
Heppner
D Gray
DG
Polhemus
Mark E
ME
D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use*; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins / Q000627:therapeutic use*; D002675:Child, Preschool; D004338:Drug Combinations; D004983:Ethanolamines / Q000627:therapeutic use*; D005449:Fluorenes / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007630:Kenya; D008288:Malaria / Q000097:blood / Q000188:drug therapy* / Q000469:parasitology; D017780:Malaria Vaccines / Q000008:administration & dosage; D010961:Plasmodium / Q000145:classification / Q000302:isolation & purification; D012008:Recurrence
D000962:Antimalarials; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes; D017780:Malaria Vaccines
Br J Haematol. 2000 Feb;108(2):295-9
10691858
Trans R Soc Trop Med Hyg. 2005 Jun;99(6):459-67
15837358
Malar J. 2007 Feb 21;6:21
17313682
JAMA. 2007 May 23;297(20):2220-6
17519411
J Infect Dis. 2002 Dec 1;186(11):1661-8
12447744
Am J Trop Med Hyg. 1999 Apr;60(4):641-8
10348241
Lancet. 2007 Feb 10;369(9560):491-8
17292769
J Med Entomol. 2006 Mar;43(2):200-6
16619599
Malar J. 2006 Nov 10;5:107
17096835
PLoS Clin Trials. 2006 May;1(1):e7
16871329
Malar J. 2006 Nov 24;5:113
17125496
Nature. 1995 Jul 20;376(6537):246-9
7617034
PLoS One. 2009;4(3):e4708
19262754
PLoS Clin Trials. 2007 May 18;2(5):e20
17525792
Blood. 2005 Jul 1;106(1):368-71
15769889
East Afr Med J. 2006 May;83(5):236-42
16866217
PLoS Med. 2006 May;3(5):e158
16605300
Expert Opin Pharmacother. 2007 Jan;8(1):75-94
17163809
J Infect Dis. 2000 Jun;181(6):2023-8
10837185
Hemoglobin. 2007;31(4):401-8
17994373
Am J Trop Med Hyg. 2006 Jun;74(6):991-8
16760509
Eur J Haematol. 2007 Aug;79(2):177-8
17608715